According to DelveInsight, IgA Nephropathy market in 7MM is expected to change in the study period 2017-2030.
The factors that shall expedite the growth of IgA Nephropathy market include increasing awareness about available treatments during the forecast period (2019–2030). Overall, the increasing Prevalence, disease awareness, and promising emerging pipeline therapies will propel the market size forward during the forecast period. A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for IgA Nephropathy.
IgA Nephropathy Market Insight, Epidemiology, and Market Forecast Analysis Report
What is IgA Nephropathy?
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build
up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody, a protein made
by the immune system to protect the body from foreign substances such as bacteria or viruses. Most
people with IgA nephropathy receive care from a nephrologist, a doctor who specializes in treating people
with kidney disease.
IgA Nephropathy Epidemiology
In North America and Europe, males are two times more likely to get the disease, while in Asia,
females are just as likely as males to be affected.
Asians are much more likely than Caucasians to get IgA nephropathy.
IgA nephropathy most often presents between teenage years to late 30’s, but can present at any
IgA Nephropathy Market Outlook
According to DelveInsight, IgA Nephropathy market in 7MM is expected to change in the study period
Currently, effective treatment options for IgA nephropathy are limited and focus on conservative
measures to arrest disease progression rather than treating the primary IgA defect. None of these has yet
been studied in large-scale clinical trials, and the evidence for their benefit is limited to small trials and
observations. The treatment of IgA nephropathy in any individual patient should be tailored to that
patient's presentation, given the conflicting results of many studies of this disease. All patients should be
given supportive therapy with renin-angiotensin system blockade and dietary sodium restriction.
Tonsillectomy is appropriate only for patients with recurrent tonsillar infections.
Currently, various drug therapy are available but these drugs are use to reduce the blood pressure and
systemically suppress the immune system. Immunosuppressants drugs can cause a range of serious side
effects, such as high blood pressure or high blood sugar and research and